ID
38390
Beschrijving
Study ID: 103414 Clinical Study ID: 103414 Study Title: A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal surgery Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00038961 https://clinicaltrials.gov/ct2/show/NCT00038961 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Fondaparinux Sodium Trade Name: Fondaparinux Sodium Study Indication: Thrombosis This phase III placebo-controlled trial studies the efficacy and safety of Fondaparinux as an additional prevention measure of venous thromboembolic events (VTE) in patients above the age of 40 with intermediate or high VTE risk undergoing abdominal surgery. The study consists of a Screening Visit (Visit 0), the baseline visit on Day 1, the day of the surgery (Visit 1), the treatment period (denoted in its entirety as Visit 2) consisting of administration of Fondaparinux (2.5mg subcutaneously once daily) or placebo starting on Day 1 and continuing at least up to Day 5, possibly up to Day 9, in parallel to intermittent pneumatic compression and possibly elastic stockings, followed by a mandatory bilateral venography no longer than 24 hours after study drug cessation, and finally a Follow-up Visit (Visit 3) on Day 30 +/- 2. This form contains whether and when the study drug has been given, and is to be filled in from Day 1 (Visit 1) possibly up to Day 9 (Visit 2), as well as the Randomization/Treatment Assignment, which is applicable to Day 1 (Visit 1) only (prior to the first injection).
Link
https://clinicaltrials.gov/ct2/show/NCT00038961
Trefwoorden
Versies (1)
- 15-10-19 15-10-19 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
15 oktober 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Fondaparinux in Addition to Intermittent Pneumatic Compression in Abdominal Surgery Patients at VTE Risk - NCT00038961
Study Drug Dosing and Treatment Assignment
- StudyEvent: ODM
Beschrijving
Study Drug Dosing
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C0304229
Beschrijving
If no, specify reason
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1533734
Beschrijving
if applicable
Datatype
text
Alias
- UMLS CUI [1,1]
- C1521902
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C0304229
- UMLS CUI [1,4]
- C1533734
- UMLS CUI [1,5]
- C1272696
Beschrijving
Study Drug Dosing - per Day
Alias
- UMLS CUI-1
- C0678766
- UMLS CUI-2
- C0304229
- UMLS CUI-3
- C2826182
Beschrijving
Fill in entire itemgroup for each Day. Note: Day 1 = day of anesthesia induction The first post-operative dose will be 6 hours following surgical closure provided that hemostasis is achieved.Timing of the first post-operative injection of study drug requires strict adherence in patients ≥ 75years, and/or with a body weight < 50 kg and/or a creatinine clearance (cockroft formula) < 50 mLper minute. In these patients the first injection of study drug should be more than 6 hours after surgical closure.The first injection must be performed at least 4 hours after removing of indwelling intrathecal or epidural catheter.The second study drug injection will be 16 to 28 hours after the first injection.The third injection and the following will be once daily at 8:00 a.m. ±2.
Datatype
integer
Alias
- UMLS CUI [1]
- C2826182
Beschrijving
If no, give date/time of dose in next item; if yes, specify reason
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0678766
- UMLS CUI [1,3]
- C1272696
Beschrijving
Select either "Not done" in previous item or give date/time of dose. The first post-operative dose will be 6 hours following surgical closure provided that hemostasis is achieved.Timing of the first post-operative injection of study drug requires strict adherence in patients ≥ 75years, and/or with a body weight < 50 kg and/or a creatinine clearance (cockroft formula) < 50 mLper minute. In these patients the first injection of study drug should be more than 6 hours after surgical closure.The first injection must be performed at least 4 hours after removing of indwelling intrathecal or epidural catheter.The second study drug injection will be 16 to 28 hours after the first injection.The third injection and the following will be once daily at 8:00 a.m. ±2.
Datatype
datetime
Alias
- UMLS CUI [1,1]
- C1264639
- UMLS CUI [1,2]
- C0678766
- UMLS CUI [1,3]
- C0304229
Beschrijving
Must be completed only once, but, in case of error in treatment allocation, it must be recorded for each Day.
Datatype
integer
Alias
- UMLS CUI [1]
- C1522541
Beschrijving
Reason dosing not done or outside requested time
Datatype
text
Alias
- UMLS CUI [1,1]
- C0566251
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C0678766
- UMLS CUI [1,4]
- C1272696
- UMLS CUI [2,1]
- C0566251
- UMLS CUI [2,2]
- C0304229
- UMLS CUI [2,3]
- C0678766
- UMLS CUI [2,4]
- C3242146
Beschrijving
Treatment Assignment
Alias
- UMLS CUI-1
- C1522541
Beschrijving
Date of randomization
Datatype
date
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0011008
Beschrijving
Time of randomization
Datatype
time
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0040223
Beschrijving
Treatment Number
Datatype
integer
Alias
- UMLS CUI [1]
- C1522541
Beschrijving
Drug Label
Datatype
text
Alias
- UMLS CUI [1]
- C0013191
Similar models
Study Drug Dosing and Treatment Assignment
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
C2986440 (UMLS CUI [1,2])
C1533734 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C1533734 (UMLS CUI [1,4])
C1272696 (UMLS CUI [1,5])
C0304229 (UMLS CUI-2)
C2826182 (UMLS CUI-3)
C0678766 (UMLS CUI [1,2])
C1272696 (UMLS CUI [1,3])
C0678766 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,2])
C0678766 (UMLS CUI [1,3])
C1272696 (UMLS CUI [1,4])
C0566251 (UMLS CUI [2,1])
C0304229 (UMLS CUI [2,2])
C0678766 (UMLS CUI [2,3])
C3242146 (UMLS CUI [2,4])
C0011008 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
Geen commentaren